Teva announces promising interim results from its study pearl, about the impact of ajovy® (fremanezumab)

Amsterdam--(business wire)--teva pharmaceuticals europe b.v. today announces promising interim results from its pan-european real world study (pearl), presented for the first time at the european academy of neurology (ean) congress in vienna, austria. the two-year pan-european real world (pearl) prospective, observational study of ajovy® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by teva pharmaceuticals eu
TEVA Ratings Summary
TEVA Quant Ranking